Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

Kazuyoshi Kawakami,1 Takeru Wakatsuki,2 Azusa Soejima,1 Kazuo Kobayashi,1 Takashi Yokokawa,1 Takeshi Aoyama,1 Kenichi Suzuki,1 Mitsukuni Suenaga,2 Kensei Yamaguchi,2 Ayaka Inoue,3 Yoshiaki Machida,3 Toshihiro Hama1 1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Re...

Full description

Bibliographic Details
Main Authors:	Kawakami K, Wakatsuki T, Soejima A, Kobayashi K, Yokokawa T, Aoyama T, Suzuki K, Suenaga M, Yamaguchi K, Inoue A, Machida Y, Hama T
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-10-01
Series:	Patient Preference and Adherence
Subjects:	adherence regorafenib colorectal cancer hand-foot-skin reactions
Online Access:	https://www.dovepress.com/factors-associated-with-regorafenib-adherence-with-metastatic-colorect-peer-reviewed-article-PPA

Similar Items

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
by: Yoon SE, et al.
Published: (2018-12-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
by: Novakova-Jiresova A, et al.
Published: (2020-07-01)

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis
by: Mikhail Yu Fedyanin, et al.
Published: (2019-09-01)

Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
by: M. I. Sekacheva, et al.
Published: (2020-11-01)

Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study
by: Wang RT, et al.
Published: (2021-09-01)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
by: Kenji Yoshino, et al.
Published: (2017-08-01)

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
by: Dominique Béchade, et al.
Published: (2017-08-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study
by: Federica Martorana, et al.
Published: (2017-11-01)

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study
by: Elisa Conde, et al.
Published: (2021-04-01)

Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib
by: Saeid Afshar, et al.
Published: (2020-01-01)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
by: Oronzo Brunetti, et al.
Published: (2019-12-01)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
by: Brice Pastor, et al.
Published: (2021-09-01)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)

FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
by: Yongjun Cha, et al.
Published: (2018-06-01)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
by: Kazuaki Matsuoka, et al.
Published: (2018-09-01)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
by: Liying Sun, et al.
Published: (2021-10-01)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
by: Jisheng Li, et al.
Published: (2020-11-01)

<i>NPY</i> Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
by: Lars Henrik Jensen, et al.
Published: (2019-10-01)

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
by: Feng Wang, et al.
Published: (2021-09-01)

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
by: A. Carrato, et al.
Published: (2019-06-01)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
by: Antoine Adenis, et al.
Published: (2021-05-01)

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
by: Goel G
Published: (2018-03-01)

Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study
by: Yukinori Ozaki, et al.
Published: (2018-02-01)

Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
by: Keigo Chida, et al.
Published: (2021-03-01)

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
by: Cao, G., et al.
Published: (2022)

Clinical cases of the treatment of metastatic colorectal cancer in Russia
by: V E Goldberg, et al.
Published: (2017-12-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
by: Pia S. Zeiner, et al.
Published: (2019-11-01)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)

Research advances in regorafenib in treatment of hepatocellular carcinoma
by: CHEN Weibo
Published: (2017-12-01)

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
by: Dennis Doleschel, et al.
Published: (2021-09-01)